<code id='1B2FD707DB'></code><style id='1B2FD707DB'></style>
    • <acronym id='1B2FD707DB'></acronym>
      <center id='1B2FD707DB'><center id='1B2FD707DB'><tfoot id='1B2FD707DB'></tfoot></center><abbr id='1B2FD707DB'><dir id='1B2FD707DB'><tfoot id='1B2FD707DB'></tfoot><noframes id='1B2FD707DB'>

    • <optgroup id='1B2FD707DB'><strike id='1B2FD707DB'><sup id='1B2FD707DB'></sup></strike><code id='1B2FD707DB'></code></optgroup>
        1. <b id='1B2FD707DB'><label id='1B2FD707DB'><select id='1B2FD707DB'><dt id='1B2FD707DB'><span id='1B2FD707DB'></span></dt></select></label></b><u id='1B2FD707DB'></u>
          <i id='1B2FD707DB'><strike id='1B2FD707DB'><tt id='1B2FD707DB'><pre id='1B2FD707DB'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:focus    Page View:398
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In